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  A patient with renal cell carcinoma producing increased erythropoietin resulted in secondary
erythrocytosis was presented．
  A68－year－old man was admitted to our clinic with a chief complaint of皿acroscopic hematuria
in April， 1977． Angiograms demonstrated a huge tumor of the right kidney with multiple liver meta－
stases． Despite transcatheteral embolization of the right renal artery and progesterone therapy，
the patient died in September， 1977． The histopathological study showed・adenocarcinoma of the
right kidney by autopsy．
  Since admission the patient had erythrocytosis， Bioassay and hemagglutination－inhibition assay
for erythropoietin were performed． The assay of the plasma， the urine and the・ extract of the tumer
showed that erythropoietin activity was significantly greater than normal value． ln view of these
results， erythrocytosis associated with the tumor appears to be secondary to the production of ety－
thropoietin from the tumor．
  The literatures concerning incidence and mechanism of association between erythrocytosis and
tumors were reviewed． A discussion was made about significance of estimating erythropoietin level























































mm3， Hb 22．2 g／dl， Ht 67．3．0／o， WBC 8，800／mm3，
MCV 77μ3， MCH 25．2μμg， MCHC 32．9％〔止血
機能〕bleeding time 2分， platelets 20．6×104／mm3，
その他の止血機構にも異常なし．〔血液化学〕Na142
mEq／l， K 5．1 mEqfl， Cl 107 mEq／l， BUN 19mg／dl，
creatinine 1，1 mg／dl， uric acid 8．1 mg／dl， acid phos－
phatase 3．6 K．A．U．〔肝機能〕total P「otein 7・0 9fd1・
A／G比1．26，GOT l2 K．U， GPT 5 K．U， LDH 386
W．U， LAP 99 GR．U， r－GTP 24 mU／ml， 1，1． 7，
ALP l 3．6 K．A．U．〔チゼリウス〕albumin 52，1％，α1－
globulin 6，9％， a2－globulin 12．2％， P－globulin 11．1
％，γ一glebylin 17．7％ 〔免疫電気泳動〕IgG 1，480
mg／d1， IgA 316mg／廿1， IgM 145 mgfdl．〔血清〕CRP


























of the right kidney with remarkable necrosis （Fig．
6）． ＠Organized thrombosis of renal artery with
recanalization． ＠The metastases to right pararenal
fatty tissue， surrounding tissue of the adrenal， the







（RBC） （Ilb） （1－lt） （Plat．） （WBC）




811万  20ダ／d8 55％  27万








813万  229／de 68％  28万













（RBC） （Ht） （WBC） CPIat）
811万 55％  10900 27万
800万  66％7200  25万
591万 50％ 10400 31万
  〔Erythropoietin活性）





  （bioassay：control値0．298％Fe59 incorporation）
薩繍畿1：：諺ll：：：ll：：：：：二：：1＝「
  （bioassay：con trol値0，298％Fe59 incorporation）
Table 3．赤血球増加を伴った疾患例



































1 田辺・ほか 196254M737万69％ 正常 正常 血漿↑
2 井上・宮川 1962 638万57％670023万 RBC正常化
3 〃 1962 600万51％690016万 RBC正常化
4 田中・ほか 196364M710万
5 Seki 1963 600万 900029万
6 岡本・ほか 196565M623万61％ RBC正常化




8 藤井・ほか 1976 6M650万63％550022万 血漿↑m腫瘍抽出液↑ ［RBC正常化Ep。．正常化
9 三方・ほか 1976 4M634万52％560032万 血漿 ↑m腫瘍抽出液↑ RBC 正常化
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